Cogent Biosciences Announces SUMMIT Continues to Showcase Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients
Total Symptom Score (TSS) at 48 weeks, including 88% of patients achieving at least a 50% reduction in TSSTop-line ...